{"id":"dc-806","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5864290","moleculeType":null,"molecularWeight":"492.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the IL-17 receptor, preventing IL-17 from interacting with its receptor and thereby reducing inflammation. This mechanism is thought to be beneficial in treating various inflammatory diseases.","oneSentence":"DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:21.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06045000","phase":"PHASE1","title":"Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-09-14","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT05896527","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-05-02","conditions":"Plaque Psoriasis","enrollment":229},{"nctId":"NCT06808815","phase":"PHASE1","title":"A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2021-09-22","conditions":"Plaque Psoriasis","enrollment":104},{"nctId":"NCT06092931","phase":"PHASE1","title":"A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-10-16","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT05994807","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-08-08","conditions":"Healthy Volunteers","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S011806","LY4100504"],"phase":"phase_2","status":"active","brandName":"DC-806","genericName":"DC-806","companyName":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","companyId":"dice-therapeutics-inc-a-wholly-owned-subsidiary-of-eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}